Literature DB >> 29635745

The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia.

Liam R Brunham1,2, Kelsey Lynch2, Amy English2, Rory Sutherland2, Jian Weng2, Raymond Cho2, Graham C Wong1, Aslam H Anis3,4, Gordon A Francis1,2, Nadia A Khan1,4, Bruce McManus2,5, David Wood1, Keith R Walley1,2, Jonathon Leipsic6, Karin H Humphries4,7, Alison Hoens8, Andrew D Krahn1,2, G B John Mancini1, Simon Pimstone1,2.   

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is highly heritable, particularly when it occurs at a young age. The screening of individuals with premature ASCVD, although often recommended, is not routinely performed. Strategies to address this gap in care are essential. We designed the Study to Avoid CardioVascular Events in British Columbia (SAVE BC) as a prospective, observational study of individuals with a new diagnosis of very premature ASCVD (defined as age ≤ 50 years in males and age ≤ 55 years in females) and their first-degree relatives (FDRs) and spouses. FDRs and spouses will undergo screening for cardiovascular (CV) risk factors and subclinical ASCVD using a structured screening algorithm. All subjects will be followed longitudinally for ≥10 years. The overall goal of SAVE BC is to evaluate the yield of a structured screening program for identifying individuals at risk of premature ASCVD. The primary objectives of SAVE BC are to identify and follow index cases with very premature ASCVD and their FDRs and to determine the diagnostic yield of a structured screening program for these individuals. We will collect data on CV risk factors, medication use, CV events, and healthcare costs in these individuals. SAVE BC will provide insight regarding approaches to identify individuals at risk for premature ASCVD with implications for prevention and treatment in this population.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Epidemiology; Genetics/Gene Therapy; Lipidology; Preventive Cardiology

Mesh:

Year:  2018        PMID: 29635745      PMCID: PMC6490105          DOI: 10.1002/clc.22959

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  41 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins.

Authors:  S Zdravkovic; A Wienke; N L Pedersen; M E Marenberg; A I Yashin; U De Faire
Journal:  J Intern Med       Date:  2002-09       Impact factor: 8.989

4.  Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group.

Authors:  P W Connelly; D R MacLean; L Horlick; B O'Connor; A Petrasovits; J A Little
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

5.  Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women.

Authors:  H D Sesso; I M Lee; J M Gaziano; K M Rexrode; R J Glynn; J E Buring
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

6.  Screening family members at high risk for coronary disease. Why isn't it done?

Authors:  J R Swanson; T A Pearson
Journal:  Am J Prev Med       Date:  2001-01       Impact factor: 5.043

7.  Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease.

Authors:  C Hengstenberg; S R Holmer; B Mayer; S Engel; A Schneider; H Löwel; G A Riegger; H Schunkert
Journal:  Eur Heart J       Date:  2001-06       Impact factor: 29.983

8.  Screening of family members of patients with premature coronary heart disease; results from the EUROASPIRE II family survey.

Authors:  J De Sutter; D De Bacquer; K Kotseva; S Sans; K Pyörälä; D Wood; G De Backer
Journal:  Eur Heart J       Date:  2003-02       Impact factor: 29.983

9.  Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring.

Authors:  Donald M Lloyd-Jones; Byung-Ho Nam; Ralph B D'Agostino; Daniel Levy; Joanne M Murabito; Thomas J Wang; Peter W F Wilson; Christopher J O'Donnell
Journal:  JAMA       Date:  2004-05-12       Impact factor: 56.272

10.  Familial lipoprotein disorders in patients with premature coronary artery disease.

Authors:  J J Genest; S S Martin-Munley; J R McNamara; J M Ordovas; J Jenner; R H Myers; S R Silberman; P W Wilson; D N Salem; E J Schaefer
Journal:  Circulation       Date:  1992-06       Impact factor: 29.690

View more
  4 in total

1.  Premature Atherosclerotic Cardiovascular Disease: Trends in Incidence, Risk Factors, and Sex-Related Differences, 2000 to 2016.

Authors:  Diana N Vikulova; Maja Grubisic; Yinshan Zhao; Kelsey Lynch; Karin H Humphries; Simon N Pimstone; Liam R Brunham
Journal:  J Am Heart Assoc       Date:  2019-07-08       Impact factor: 5.501

2.  Priorities for Services in Young Patients With Atherosclerotic Cardiovascular Disease and Their Family Members: An Exploratory Mixed-Methods Study.

Authors:  Raymond Y Cho; Jian Weng; Kelsey Lynch; Phoebe Ng; Chad Brown; Alison M Hoens; Kevin Barry; Liam R Brunham; Simon Pimstone
Journal:  CJC Open       Date:  2019-03-06

3.  Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right.

Authors:  Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2020-07-15

4.  Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation.

Authors:  Diana N Vikulova; Ilia S Skorniakov; Brendon Bitoiu; Chad Brown; Emilie Theberge; Christopher B Fordyce; Gordon A Francis; Karin H Humphries; G B John Mancini; Simon N Pimstone; Liam R Brunham
Journal:  Am J Prev Cardiol       Date:  2020-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.